Halozyme's lead drug flops in PhI­II, forc­ing CEO to ax 160 and re­set fo­cus on tech plat­form

Halozyme’s lead drug has crashed and burned in Phase III, forc­ing CEO He­len Tor­ley to scrap the en­tire pro­gram, trig­ger a com­pa­ny re­struc­tur­ing to …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA